CIK 0001178670 · Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 770602661
- Phone
- (617) 551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $543,126
- in 2 filings
- Open-market sales, last 90 days
- $398,855
- in 1 filing
Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-08 | Bertozzi Carolyn R Director | Grant or award | +775 | 775 | ||
| 2025-05-08 | Bertozzi Carolyn R Director | Grant or award · Stock Option (right to buy) | +1,558 | 1,558 | ||
| 2025-05-02 | Greenstreet Yvonne Chief Executive Officer | Gift | −41,311 | 57,324 | ||
| 2025-04-16 | Reitan Colleen F Director | Sale | −36 | $232.86 | $8K | 0 |
| 2025-03-24 | Garg Pushkal CMO & EVP Dev & Med Affairs | Option exercise 10b5-1 | +5,445 | $42.22 | $230K | 25,666 |
| 2025-03-24 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −5,445 | $300.00 | $1.6M | 20,221 |
| 2025-03-24 | Garg Pushkal CMO & EVP Dev & Med Affairs | Option exercise · Stock Option (right to buy) 10b5-1 | −5,445 | 0 | ||
| 2025-03-24 | PYOTT DAVID E I Director | Option exercise 10b5-1 | +7,440 | $88.95 | $662K | 7,576 |
| 2025-03-24 | PYOTT DAVID E I Director | Sale 10b5-1 | −7,440 | $299.00 | $2.2M | 136 |
| 2025-03-24 | PYOTT DAVID E I Director | Option exercise · Stock Option (right to buy) 10b5-1 | −7,440 | 0 | ||
| 2025-03-21 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −4,321 | $285.00 | $1.2M | 20,221 |
| 2025-03-13 | SCHULMAN AMY W Director | Option exercise | +2,750 | $131.21 | $361K | 11,186 |
| 2025-03-13 | SCHULMAN AMY W Director | Option exercise · Stock Option (right to buy) | −2,750 | 0 | ||
| 2025-03-04 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −121 | $239.24 | $29K | 14,224 |
| 2025-03-04 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −328 | $240.95 | $79K | 13,896 |
| 2025-03-04 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −324 | $241.68 | $78K | 13,572 |
| 2025-03-04 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −71 | $242.93 | $17K | 13,501 |
| 2025-03-04 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −147 | $239.25 | $35K | 25,203 |
| 2025-03-04 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −343 | $240.92 | $83K | 24,860 |
| 2025-03-04 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −198 | $241.60 | $48K | 24,662 |
Page 30 of 41 · 816 trades